A third study on the use of orally administered anhydrous crystalline XXXX for relief of @entity2133 in primary @entity244 .

@entity1 @entity2133 @entity244 @entity7969
OBJECTIVES: To examine the safety and efficacy of anhydrous crystalline @entity7969 for treatment of @entity2133 and other symptoms of dryness in @entity1 with primary @entity244 . DESIGN: Anhydrous crystalline @entity7969 was delivered orally as a 200-mg lozenge given three times daily over a 24-week period to a total of 100 subjects. All @entity1 had prominent complaints of persistent @entity2133 associated with primary @entity244 . @entity1 were examined at baseline and every 6 weeks of treatment. SETTINGS: @entity1 were seen in outpatient clinics at a total of 27 sites within the United States. OUTCOME MEASURES: Unstimulated whole saliva output, a measure of basal salivary gland function, was determined at each visit. Symptoms associated with oral and ocular dryness were assessed at the same time with the use of 100-mm visual analogue scales. Safety was assessed by physical examination and laboratory studies. RESULTS: During this clinical trial, a majority of evaluable subjects (39/76) demonstrated an increase in unstimulated whole saliva output, and the treatment exhibited an excellent safety profile. The anhydrous crystalline @entity7969 treatment led to significant improvement in several subjective measures of oral and ocular comfort. CONCLUSIONS: In this study, anhydrous crystalline @entity7969 lozenges administered three times daily for 24 weeks improved salivary output and decreased complaints of @entity2133 and eyes in @entity1 with primary @entity244 . Side-effects were minimal, and treatment was without significant adverse events. These results are similar to the benefits observed in two prior studies reported by the authors. This safe and simple intervention appears to provide clinical benefit to primary @entity244 @entity1 with distressing @entity2133 .
